0001104659-23-095577.txt : 20230828 0001104659-23-095577.hdr.sgml : 20230828 20230828073523 ACCESSION NUMBER: 0001104659-23-095577 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230828 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230828 DATE AS OF CHANGE: 20230828 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Apogee Therapeutics, Inc. CENTRAL INDEX KEY: 0001974640 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 880588063 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41740 FILM NUMBER: 231210164 BUSINESS ADDRESS: STREET 1: 221 CRESCENT ST. STREET 2: BUILDING 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 650-394-5230 MAIL ADDRESS: STREET 1: 221 CRESCENT ST. STREET 2: BUILDING 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Apogee Therapeutics, LLC DATE OF NAME CHANGE: 20230420 8-K 1 tm2324402d1_8k.htm FORM 8-K
0001974640 false 0001974640 2023-08-28 2023-08-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

WASHINGTON, D.C. 20549

 

 

FORM 8-K 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 28, 2023

 

 

Apogee Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

Delaware 001-41740 88-0588063
(State of Incorporation or
Organization)		 (Commission File Number) (I.R.S. Employer Identification
No.)

 

221 Crescent Street, Building 17, Suite 102b,

Waltham, MA, 02453

(Address of Principal Executive Offices, including Zip Code)

 

(650) 394-5230

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange
on which registered  
Common Stock, par value $0.00001 per share   APGE   The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 2.02Results of Operations and Financial Condition.

 

On August 28, 2023, Apogee Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. 

 

This Item 2.02 and the Press Release attached hereto as Exhibit 99.1, insofar as they disclose information regarding the Company’s results of operations and financial condition for the quarter ended June 30, 2023, are being furnished to the Securities and Exchange Commission.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits. The following exhibit is being furnished herewith:

 

EXHIBIT INDEX

 

Exhibit
 No. 		   Description
   
99.1   Press Release, dated August 28, 2023
   
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Apogee Therapeutics, Inc.
     
Date: August 28, 2023 By:

/s/ Michael Henderson

    Michael Henderson
    Chief Executive Officer

 

 

 

 EX-99.1 2 tm2324402d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results

 

$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into 4Q 2026

 

Phase 1 clinical trial initiated and first participant dosed ahead of schedule for lead product candidate, APG777, a fully optimized and half-life extended anti-IL-13 antibody for the treatment of atopic dermatitis

 

Leadership further strengthened with appointments of industry leaders to its board of directors and executive team

 

San Francisco, CA and Waltham, MA, August 28, 2023 - Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today provided a review of its pipeline of potentially best-in-class monoclonal antibody (mAb) therapies for I&I diseases, along with key anticipated milestones and recent business progress. In addition, Apogee reported second quarter 2023 financial results and provided guidance on its projected operating runway.

 

“We have achieved remarkable growth and progress across all aspects of Apogee’s business in 2023 to date, marked by the important milestones of transitioning to both a publicly traded and clinical-stage company,” said Michael Henderson, M.D., Chief Executive Officer of Apogee. “In the last year we have made noteworthy progress in our mission to develop therapeutic options for patients by advancing novel, potentially best in class antibodies that we believe may significantly improve upon standard of care. Our broad pipeline has the potential to overcome limitations of existing therapies for AD, asthma and COPD. And we have capitalized the company with an upsized IPO consisting of new and existing top tier investors that provides sufficient funding to support our operations through multiple clinical catalysts for our lead programs. We have attracted an incredibly talented and passionate team of industry leaders and experts across our board of directors, R&D and business operations. This is an exciting time for Apogee, and we are confident in our ability to deliver value from our potentially best-in-class therapeutic candidates to benefit patients living with I&I diseases.”

 

Pipeline Highlights and Upcoming Milestones

 

●Enrollment advancing in Phase 1 trial of APG777, with initial data expected mid-2024: In August 2023, Apogee announced initiation of dosing of healthy volunteers for APG777, a novel, subcutaneous (SQ) extended half-life monoclonal antibody targeting IL-13 – a critical cytokine in inflammation and a primary driver of AD. The Phase 1 trial is a double-blind, placebo-controlled clinical trial designed to evaluate the safety, tolerability and pharmacokinetics (PK) of single-ascending and multiple-ascending doses of APG777. Apogee expects initial safety and PK data from the Phase 1 trial in mid-2024, a potentially key de-risking event given APG777 is targeting a validated mechanism and has the potential to show significant differentiation compared to leading therapies. Pending positive PK and safety data, the company plans to advance into a randomized, placebo-controlled, 16-week Phase 2 proof-of-concept trial in moderate-to-severe patients with AD in 2024.

 

●APG808 development candidate selection expected in 4Q 2023: APG808 is an SQ extended half-life mAb program targeting IL-4Rα for the treatment of COPD. In head-to-head preclinical assays, Apogee’s lead candidates have demonstrated equivalent or better potency in the inhibition of IL-4Rα signaling to the current standard-of-care.

 

●APG990 program progressing as a differentiated OX40L-targeted opportunity: APG990 is an earlier-stage SQ extended half-life mAb program designed to target OX40L, which occurs further upstream in the inflammatory pathway than IL-13 or IL-4Rα, which may lead to an expanded effect on the inflammatory cascade. Targeting OX40L represents another potential treatment approach for AD, including for patients who do not benefit from currently available therapies. Apogee expects to select a development candidate for its APG990 program in 2024.

 

 

 

 

 

●APG222 program advancing with a dual mechanism targeting both IL-13 and OX40L: APG222 is one or more SQ extended half-life mAbs targeting both IL-13 and OX40L, for the potential treatment of AD and other I&I indications. By blocking OX40L and IL-13, APG222 could simultaneously decrease OX40L signaling, helping to rebalance the immune system and decrease immune cell differentiation and cytokine release, and further reduce IL-13, resulting in even less immune signaling. This approach has the potential to prevent certain disease-related signs and symptoms that are driven by IL-13 signaling and the downstream inflammatory cascade.

 

●Multiple pipeline expansion opportunities, including through Paragon collaboration: In addition to each program’s initial indication, Apogee’s programs have the potential to expand into a range of I&I diseases. The company has identified asthma as a leading expansion opportunity for APG777 given the significant overlap with AD and the unmet need. In addition, under a strategic collaboration agreement with Paragon Therapeutics, Inc., Apogee plans to select and evaluate additional targets that have the potential to overcome the limitations of existing therapies by engineering best-in-class antibodies.

 

Recent Corporate Highlights

 

●Appointed Mark C. McKenna as Chairman of the Board: In August, Apogee expanded its board with the appointment of Mark C. McKenna, former Chairman, President and CEO of Prometheus Biosciences, Inc. which was acquired by Merck & Co., Inc. in June 2023 for approximately $10.8 billion, representing the largest pre-Phase 3 biopharma acquisition to date. Mr. McKenna’s knowledge and successful track record in the I&I space as well as his significant development, commercial and executive management experience contributed to the Apogee board of directors’ selection decision.

 

●Designated Matt Batters as General Counsel: Also in August, Matt Batters was appointed as General Counsel. He was previously General Counsel at Arvinas, Inc., a biotech focused on oncology and neurological diseases where he built its legal team as it moved from a private, preclinical company to a public company, led the alliance management team in supporting Arvinas’s strategic collaborations, and, before becoming its General Counsel, also led its business development activities. Previously, Mr. Batters was a Senior Director on the legal team at Alexion Pharmaceuticals (now part of AstraZeneca) where he supported the business development function, and was responsible for structuring and negotiating Alexion’s licensing, collaborations and M&A activities. Prior to Alexion, Mr. Batters was a corporate associate at DLA Piper and Skadden, Arps, Slate, Meagher & Flom, where he advised pharmaceutical and biotechnology clients on global corporate governance, capital raising and securities matters, as well as complex licenses, collaborations, and M&A transactions.

 

●Completed $345 million upsized Initial Public Offering (IPO): In July, the company completed its upsized IPO and sold 20,297,500 shares of common stock, which included the full exercise of the underwriters’ option to purchase additional shares at a price to the public of $17.00 per share. The aggregate gross proceeds to Apogee from the offering before deducting underwriting discounts and commissions and other offering expenses were approximately $345 million.

 

●Strengthened team with Board of Directors and Management Appointments: In June, Apogee further strengthened its leadership team with the appointments of Jennifer Fox and William “BJ” Jones, seasoned financial and commercial executives, respectively, to its board. In addition, Rebecca Dabora, Ph.D., an expert in chemistry, manufacturing and controls (CMC), was appointed Chief Technical Officer.

 

 

 

 

 

Second Quarter Financial Results

 

●Cash Position: As of June 30, 2023, Apogee had a cash balance of $125.1 million. We expect that the Company’s existing cash, together with the gross proceeds from the upsized IPO of approximately $345 million will enable it to fund its current operating expenses and capital expenditure requirements into the fourth quarter of 2026.

 

●Research & Development (R&D) Expenses: R&D expenses for the second quarter of 2023 were $13.9 million, compared to $1.4 million for the second quarter of 2022. R&D expenses increased primarily due to APG777 and APG808 program advancements and increases in personnel costs, including share-based compensation expense associated with the growth of R&D team.

 

●General and Administrative (G&A) Expenses: G&A expenses for the second quarter of 2023 were $4.9 million, compared to $0.4 million for the second quarter of 2022. The increase of $4.5 million was primarily attributable to the increase in personnel costs associated with increased headcount and legal and other professional services conducted to support the growth of the business.

 

●Net Loss: Net loss for the second quarter of 2023 was $18.9 million, compared to the net loss for the second quarter of 2022 which was $1.8 million.

 

About Apogee

 

Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering properties, including half-life extension. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit www.apogeetherapeutics.com.

 

Forward Looking Statements

 

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, our expectations regarding plans for our current and future product candidates and programs, plans for our current and future clinical trials, plans for clinical trial design, the anticipated timing of the initiation of and results from our clinical trials, potential clinical benefit and half-life of APG777, APG808, APG990, APG222, and any other potential programs, potential additional indications for APG777, the anticipated timing for selection of development candidates and our other programs and expectations regarding the time period over which our capital resources will be sufficient to fund our anticipated operations. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Apogee believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Apogee’s filings with the U.S. Securities and Exchange Commission (the SEC)), many of which are beyond the company’s control and subject to change. Actual results could be materially different. Risks and uncertainties include: global macroeconomic conditions and related volatility, expectations regarding the initiation, progress, and expected results of our preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of our clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in our Registration Statement on Form S-1, as amended, declared effective by the SEC on July 13, 2023, and subsequent disclosure documents we may file with the SEC. Apogee claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Apogee expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

 

 

 

 

 

APOGEE THERAPEUTICS, LLC

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(In thousands)

 

   JUNE 30,
2023		  DECEMBER 31,
2022		 
Assets         
Current assets:         
Cash  $125,069  $151,890 
Prepaid expenses and other current assets   5,598   165 
Total current assets   130,667   152,055 
Total assets  $130,667  $152,055 
          
Liabilities, preferred units and members’ deficit         
Current liabilities:          
Accounts payable   $11,148  $418 
Accrued expenses   6,467   9,562 
Total current liabilities   17,615   9,980 
Total liabilities   17,615   9,980 
Commitments and contingencies         
Series A Preferred Units; 20,000,000 units authorized, issued and outstanding as of June 30, 2023 and December 31, 2022; liquidation of $20,000 value as of June 30, 2023 and December 31, 2022   28,971   28,971 
Series B Preferred Units; 45,089,212 units authorized, issued and outstanding as of June 30, 2023 and December 31, 2022; liquidation of $149,000 value as of June 30, 2023 and December 31, 2022   148,496   148,496 
Members’ deficit:         
Common Units; 5,000,000 units authorized, issued and outstanding as June 30, 2023 and December 31, 2022   2,251   2,251 
Incentive Units; 16,537,557 units authorized, 14,270,275 issued and 2,481,543 outstanding as of June 30, 2023; 12,412,473 units authorized, 9,648,374 issued and 1,625,086 outstanding as of December 31, 2022   4,529   2,142 
Accumulated deficit   (71,195)  (39,785)
Total members’ deficit   (64,415)  (35,392)
Total liabilities, preferred units and members’ deficit  $130,667  $152,055 

 

 

 

 

 

APOGEE THERAPEUTICS, LLC

 

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

(In thousands)

  

   THREE MONTHS ENDED
JUNE 30,		  SIX
MONTHS ENDED
JUNE 30,		  PERIOD
FROM
FEBRUARY 4,
2022
(INCEPTION)
TO JUNE 30,		 
   2023  2022  2023  2022 
Operating expenses:                 
Research and development  $13,946  $1,448  $22,401  $5,693 
General and administrative   4,939   368   9,142   428 
Total operating expenses   18,885   1,816   31,543   6,121 
Loss from operations   (18,885)  (1,816)  (31,543)  (6,121)
Other income (expense), net:                 
Interest income   —   —   133   — 
Total other income (expense), net   —   —   133   — 
Net loss and comprehensive loss  $(18,885) $(1,816) $(31,410) $(6,121)

 

Investor Contacts:

 

Noel Kurdi

VP, Investor Relations

Apogee Therapeutics

Noel.kurdi@apogeetherapeutics.com

 

Alex Straus

THRUST Strategic Communications

alex@thrustsc.com

 

Media Contact:

 

Dan Budwick

1AB Media

dan@1abmedia.com

 

 

 

 EX-101.SCH 3 apge-20230828.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 apge-20230828_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 apge-20230828_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2324402d1_ex99-1img001.jpg GRAPHIC begin 644 tm2324402d1_ex99-1img001.jpg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htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 28, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 28, 2023
Entity File Number 001-41740
Entity Registrant Name Apogee Therapeutics, Inc.
Entity Central Index Key 0001974640
Entity Tax Identification Number 88-0588063
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 221 Crescent Street
Entity Address, Address Line Two Building 17
Entity Address, Address Line Three Suite 102b
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02453
City Area Code 650
Local Phone Number 394-5230
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol APGE
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 tm2324402d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001974640 2023-08-28 2023-08-28 iso4217:USD shares iso4217:USD shares 0001974640 false 8-K 2023-08-28 Apogee Therapeutics, Inc. DE 001-41740 88-0588063 221 Crescent Street Building 17 Suite 102b Waltham MA 02453 650 394-5230 false false false false Common Stock, par value $0.00001 per share APGE NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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`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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://apogeetherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2324402d1_8k.htm apge-20230828.xsd apge-20230828_lab.xml apge-20230828_pre.xml tm2324402d1_ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2324402d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2324402d1_8k.htm" ] }, "labelLink": { "local": [ "apge-20230828_lab.xml" ] }, "presentationLink": { "local": [ "apge-20230828_pre.xml" ] }, "schema": { "local": [ "apge-20230828.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "APGE", "nsuri": "http://apogeetherapeutics.com/20230828", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2324402d1_8k.htm", "contextRef": "AsOf2023-08-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://apogeetherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2324402d1_8k.htm", "contextRef": "AsOf2023-08-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apogeetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-095577-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-095577-xbrl.zip M4$L#!!0 ( &L\'%=/0OJ-- , $, 1 87!G92TR,#(S,#@R."YX M],_T'U:\88PR0% LE0DK1T2).!D*1YZQY, O0 7A-&689?*!@+J,H_043GZ_=\9<:?QH.[N[D2?7ATAE^35TVA3N&"4:J&%2T M#)U?EMZT6F)\9%7*9=MZO.X-$IR1 AMQ0.CS.KA=K]>M9#>'%I"QPX-$_."(O@8RO=7(*2M="3%$IRJ ++6A M\)5J#HR$.<(XG(%]+)Q$--M8 @LNBT!E7 69\C4$L1::;BT1VK>?+V=8'+(1 M@!RK>0@ADL1-NC/!EVN5FIJQ "9 Y17CDPOP<12HD'Y%." ^ <] $O,12-UN M(L0N[*R;=R^FE*DF5Y.66;0M#(GJXIE!F735&YP%<*?207JAINPM9QIF=9BZ M,PQ$O):1+A=D#?T+%F''(2B M)\GUE"'C9Y#M7!<';A0<1)W'MXV9V?,C+9QU/F9]\%$RG@W=2"U#$'U!&IEM MS,%O&3@<@9E7]H=*NZ0:+8=H#UO&,ZG1ZDEECG,)S-V"2N'Z4"(L!"Z)ZO:% M.R(-G4A-OUUP@[0?82#K'V8>8&??S!4%@O^8P^'WYBQ@2F;V"6"JG)[FE);1H MQ51UK-J;PWF+F;R+@YK 91&5_'6?1EBDY"^'56/^9[!;(7)\6@3]LW"HVP.Z MH.A\70LTK51-+?\ 4$L#!!0 ( &L\'%>5A8&!_@H ("& 5 87!G M92TR,#(S,#@R.%]L86(N>&ULS9U=;^.X%8;O"_0_<-V;%AC'XP0MD.QD%QE/ MLC VFV1CSVS;1;&@)<810I,!)2?VOR\IB;)$\4A*BI*(I/8KX9EB%BPQGV[2J[>/N8_FG"/]$$_9TIOY:X90@>;Q8>K9+D_.1 MVF^YV]>3(R[6D^./'Z>3?_YRO8@>R0:/$Z:.6T1&.DK58HN;GIZ>3O)2+6TI M=RM!]3Y.)MI.5;,L33KT-2=I*0/?GX$!:?DGCR@O)EGV?Y9HI0FBH11N>U1D >[&2K$1,5/&%GCC,1J M1Z=J1]-_J!W]I=Q\C5>$CI!22C[ =ITVZBJ#)J[-WA&1\/B2O<^U&>W)OOSN MB.Q_:$ ]WGD3ECS#]%WFZY'.;=^0]QWQ0YS[(RW'>?*^(UV+_+_8SMJ6WWQX M[<>5JHW7\E/#(MEE<@(CL3:IJN@8@?,]Y!-#67=5.X\:]5(UFG/1;KN:&?,Z M4Q(=K?G+)":)K/OX1'T8JP]YL^5__IAQN1*X6*69P%&F:\J;<3ZRE$],2TIY M(;0O+**>QI6*2<3EU/2:6PC_HJHHO#HOZJBZVV M=!\W"H/H9)LCLYK!,UM2@+ZOR6J(T=PQB@=SWT=]HVYP*K. AHAC@$9XMZ$*JB/'%T MP=@6TWORS$47/DV9:VIL)DU8ZIJ@&+$8 ]$HM*@0>R+BUZT\8R>"[GNA:"E= MB%I2YV?;@!F6Z<>ABXH3@!S\"E) MI?=+RN*14*KN!V#6/Z#8Q*YI@0V;O+2501$#V@.9R2-0&1(.-IAEM(U/8!5DQM#%A0Q=F\@ M*X4! BE'E2FY+.YIG MT;H&!+1K0M(2!@4*Y Z$I0C0S.0A7H'Y%\%B&"XUI1]86E;MJ%2R $$QO?5A MHO1>()EMA6BXAF<<6.KLIFR/V>K^+* + I0>B294FV5\_3 MW6PW*R(LC6M+7+$!F=-,F.5!L "8,ADH9$CI4"'TTO/Z+@'+U$.,8'-,F5L" M[":;%#0U 9%@-0;0<-#FSY1Z(6(F1R:!Z9S%9/+2P]MIO, .* T.EV"! D@U SRB=(O *D: MO!!W$2OMH>S0:479-I6K< <9.'ATO+6!XL*4.L9%>(3DWQA=2ON!'])6 0O MF2&Y%V TU9J#&UXZ-@-]O%3+8AUG->QIEB4]WY)M,S/*-,T:1]B"DUXD#2- M]0XNA=HG$G<\S3#]=_+<>2)N%WO!PVK8"DE#&1XJ-GM]P!0Q2 ;Y.+$N<54W M-*RODAGE[EX!MM@ZO )<*PP" INC]BO Q=630N2ZFQ6C@F!@1&@6.^MDBZFJ MCVME871QVU"KA_/OM=3X^"*K["[T[I$S^ &!ML153T/F=&^;Y4'T.&#*[/5< MAG*=IZOQ*L-$:A^^:V7.9G;33C61ZX(@>M=TTYJF=;GCWOQ-))G<\XQO-EM6 MWN6Q/3<(Z%SU-641"]W^7,)*'4HJ;8,18+3I,HR1*V_D6>?(H$VUIE M$[D" C:H:6@K@D !M&5R"'A,&6M^QXDRE MYQ>;?/]7\H.EE8#.64[++IM54DN;* A&NIRUTEH62>=J8J34KKG8QDE&XL+, M5<(PBQ),J_2(MBOB_2'.:!EHO@*G1Q\&0\-,MG JPG0NPRKPD.K2]:7TX@&, MWPBE/S/^RA8$IYR1N+B68KM3U*UW^\1,C^WF0S. . B,G%85T M6'DES M)WSC=L@R+_%UR81N9 )U;<@";36(,44"DV)T!A%1B5*C]O*!=9(^H M%EG%[PZ!#83DCE_7[C1MO+5MU0;$3*=!Z!WN,N?'86U<1'EZQ3(CZOX] :V%Y*[?JFRR[3Y-J5-&Q!"G0;!]R>K&)4J!FNFO*6,$3.YU%KSCJ?$ M#97[Q#$MB^W<,94D(#QLOCHRR BDM5Y86&PPI9^W:<)("D]$ALHM"U:+318: MDH!8L/D"6,BE2&N]L'"Y(6(MI[>?!'_-'LO\K&#; +5;-CHM-QFQ2@-BILL-S]"2 MHZ\I0=DC09?ES]#5,\$7]?CZI9$H4B]$%*MR%F-A0ZA+[/Q71T##K=\>:2F# M *G7'OP[)%4$TB&.J;F5#(OZ>5QN8IZ1#?BV0W^(*X*&FM<<]>F#H&F@29.I M/*QY48_@J2T/C.&->VYZ1+.\@"(B MBLH15XN1+G22_]_QNQ);)^S:'\G>$2( M>LHJK4:KONMO Z/=,O.F)C5I&A0:$&=O\0L0>*@"U>KX4)NQ?%[,4P^-JVQN M/'I:/&)Y &^W6:IF4&D,O@K>&>3X]L* !A@W&3HB D)O@$WHAD,>B?+0#Z@( M1K5H3^=GZ2$+((D_[^_) Q'JO8,EV66?Y8Z>.LXP!L2Z/GL;W!SS9*XW, @( MW^H6.M5+4;T"M%+/B)55H-]5)2BOQ?;[Y?5-U_*3W*PWR;]6."5RRW\!4$L# M!!0 ( &L\'%>ZP5'270< .E7 5 87!G92TR,#(S,#@R.%]P&ULS9Q=<]HX%(;O=V;_@Y>]!@+9CR9-MI/0T&&:-MF0MKM[TQ&V $UDB9'D M /]^)1M3/BSYY,8GN4B(.9+.^QQ9]K$D7[Q;I3QZIDHS*2Y;OB_C]DA, MY=OH,TGI>?2!"JJ(D>IM])7PS!V10\:IB@8R77!JJ/VB:/@\^KW3.YM$[3:@ MWJ]4)%)]>1AMZYT;L]#GW>YRN>P(^4R64CWI3BQ36(5C0TRFM[6=K$XV/T7Q M"\[$T[G[-2&:1I:7T.EZ9'E:J)XV<9IMW1G6[/]E@7L=SS1[%SG[MW*F)@\ M[+7-1%X+]U^[-&N[0^U>OWW:ZZQTTBKAYP25Y/2!3B/WUT9OVRI9R!FE9FX[ MRX)FAL5YZ+K.K#N0MFM:G_,*YHI.+UMD,7/M]$]/WO3?N%9^W3,RZX7MHIJY M'M:*NGL>+!355)A<]*T]L%>$KHSM6#0I*W+MO]Q'PXPKMNE O:CM>EN6VE;M MQ\)RXU+I%)?QGA_<144>B"Y[>,Y>T[@SD\_=A+*N ^$^Y$1R&O:?[WE#5Q-M M%(E-61,G$\KS^K];FP.3;@->E20>;8W53NU;'/JT&[XK%4=2)519UF5=1,5[ M03ONK!N+[H(H6U$[GC.^C?=4R=1'9T-">AS=!66;:(;FE6T_<3X,.9E5XSPP M ?+L80"M5(-%]#W5L6(+QZ4&[)XED&\?E6^%MH8QE^?. YTQYZ]SQ5V"J3L8 M'A<\18#@3S%'BJ!:I A<"9$1_D 74M6 W[<$\OX-DW>5-B3,?V=$&:KX&D+Z MR!@(^W=,V!Z%2+P?%1&:.3X0X,?60.)_H-YX>#0B(1_/*>.'1T![38=P5YE#D*#EGK4Q4[/]2 MHL#0=XRAR%'2T!J)#0,?9$KM.1,<5?S64.0H"6B=R(:9WPC#S-K- WS.TLF/ M!Z?[K(^MH(Q1DDZ?*!2VY9,&8=ST1HCOH264,4JN&1*'PGE@]2C"1R*AJX]T M'0)]9 HEC9)C!N6AH+Y7+"5J/69Q_:!Q; N%C9)9A@6BT'XDJU%B5;$I*R8( MZZ%[BT#9HZ25(+DH(1B)6*J%W'E(2I&>#7G*CLH9)1DSR^L8<+WBKI(4WO; MG:_C ],H&!1,KM*.4ACPLTJGA,QH_[5"]664, HF5Y('-K8.P.-O;,7 MCKTH&9]/%!+;8FVX/:/N)IS-B'\G6; >)\-)O& U*;W[^5;?MS.;I7F?@SM MAVKL'E,H<)PMDB%Y3:/.$F9H4K@T9(*(V*94VWUMGNR\OA0T #A[*(&B41[O M?Z.XM HX XAU@C%R4$7R7/+"65+P15GG/ 8PI% MCCAWZ)&'L_:R6-2\O?84K_ ($?>5@()'G$0,BT5:GV:H\YD]T_?$D(V'(?Z^ M$E#^B!.*8;%HZ^?5P%YX9C(\9WY@"*6-N!2V4AH*Y'%*.+_.-!-4!\>6 T,H M9,0UKY724"#?I%3-[*#V0PI H2.N; U*Q8&_^K&/O-C_%B1? M80U^.P$B=J](K-=NQ+%;2%%%^^ M9P;EBYB%5LA"P7M-Q)/*%B9>WRL94^JF3_3V; ,D1, *H"%!S$]?A +G<8%, M4[>92,9/X[D5K>\RD[_1U/H7?&@0+ <-#>8F3H!PI+L@_6.C%TVNUP]T2I5; MIO!(5^;:-O04OBD"%(?&!_6-0F ,%6&ZZ![INK4'W#MKBV_<+_=>5GOD?U!+ M P04 " !K/!Q7I=_ZIKT2 "9:0 $@ '1M,C,R-#0P,F0Q7SAK+FAT M;>T];5?BO+;?7^=O7>2>OS?\5!'SX39U#0^IJ1,+H6(H9H: M-?H?4Z[32Q^F_EO9WCH>.- /^AKVQ]3 <:QR-CL:C3*C?,9D_:Q4*I6R8]XG MY74JCV/[R;F8Z2K$]NUZ'5U@J[4-@NR=+",#J_'=, XJ:_$:08.R=>3 M]N=9=R>^_ZQKUF'8L'LF&V('YI!#*J9S#P%)VT2- (+OF;[Y_"* M"N L3$Z44]ZL8'LJ<8W,B3O "0TP0LX''1GI)8+=ST)KT-&UTWV,K6GG'K85 MT=%OB$"%9\S4B1W;6[1$NJNF:SAL$D^QWQ@98#-G$30\C'2JMLX:TU[8,ON$ M. /"L$5KH?.V!,_T0S^Q#P.PK M(!9.IJ/>,KS8>""@<< )_-\P0):3&@B)8;UI:&1\028/.?!*I8/"?B'W&KBE M$-SJD!@:_'5.==Q_Z&'=)J\ M7\"$J\_2 ^^L_!@PJ/7P) ?.@/,B/T@/PC? MZ &QQ;/7P*ES6EH^K/P"28G %5.;(-N9Z.1CJ@>*6$92SG)0EPZARQ49H;8Y MQ,:>]V /"&"T)U1>H\_!.(W:EHXG9628!A&-=%SFNDL8-PKQC6H:,82)\*_0 M\I&I?][BN< <&EH4,X!3 $UJ.U8!49:8"Q]D(V+=CBNA$ MJB*4(A9X-L(6QP4^CS!8AHGM]>"NM6R+-1.0(K$0E@?";V*K3]*!663&MI;R MFQUP"1]3-AU:.O'<@(\J"MQ#9YLN"[!!-S''99]-1+4%-@,7%70E0JK3I]/G M5.,M/4H8$N23V$6HUKR(SL#\X!FZ;"P^'YL%,C6U12H@$F!.'3ND,F,A@#1K M6Q@&TYDL"!0WRI#-NBYA,#O'6=A/'SR/\=6X"N'F/6I44:Y M5.4__Y;V[>:O0H5RJ+$/92%]6"T+6R$ ?O"*X2%Q_LDTK$^UCN-VFV[V6TV.JAZ54>- MK[5/U:NS!JI=7UXV.YWF]17Z(P3R8D2RJD"^5#N?FE=GW>NK/53/U#)(SA4+ MI:5"6!/R)&-?M,TYV]L0!9M5O-/K]B7R)IZO-#Q$+>4D$7FGTW53=7F Q;.? M!W6:),S2A1]W9U]HO]#6)BI$8&^*XL(X4I7#],5\".>K7""4V?QO3 ? U<+T M]ADDI5I:-763E=%H0!TB)+9(R,_7D;=3^-.( '_6;EQU4;O1NFYW?S$Q+9?9 M+C87U%T](4GY[RV1(*NYHN[^81K.'()OGY+F,.A0P-<;J !M]LKU5 M51T$[5(I7_B%'G#=/IZ'^)RM-K%,YJ"=X#O!$+X1VT'D&3HC)IJ)MEL&8N8\ M577.4[5$@M#PTH=XEX7/5:DEWRO]K\57N2RO,M 0-5#3L;>W:I##P=#=]5*W7$S&4K^ICD=+ 8ZMFR(M8.?1''.$=FIHP5(G@D# M)<%Z,&G _Q'RB4DSVA\ "7G+F3W322]X%+<<^:3D\Q_B@O\>'E)]4GZ)GW#: MF>.90HS-U2(V!RIN,O#I8A^DXX!SK'GU_YJI)9B@ 3^?JGS]G]TM.CLQV8T,GN+,IV+22ER(" M[^)QTZ^OJD*9EDG_[,#\YE[<=DY+A^^2?@)2R*L.T[GBX6%N?WG8,=-<^(=M MW@6M>49VA,'R12MBQLADQPKS2O37K(\-^D,\WUUJKK&<)BV9-7,XI#;?XT?< M I G]]V?H>'KEF$ST\YT,J@QM'1S0AB**M14D%=F9D%^@=)DQ=+YEHKJZLMH MG*E["+RP(,>EY3\(2J9)EEN/6&Y5TQBQ;?_C,S6(%&^UVO7YIX/&G=T=O[7X MD8@P59%E"=7@.^<-=1Q&B)-@NGL+]9O3%_B1X_DYUX;GIID;W3[B-?,CIRHG M+M6Y,B/I8&4^JB_PD4^(UR]EJ]YNN><_U#7SD4]5.BXD[*"ALI+$QGOCX'=I M-N!&,1H>*\D:_'C-NN;(B)-$;GC=;U?.#^EJ,= YGJG)9?9\ZMTR(2?5OU$H.?C_? M=VX.=.8HZV$A@A&B-+E0W%0Q8AVJO..3S9?U%@.A4POKJ#$F*F3,SP1=]V!M MXCBA27>%BP'>$&?NW26]]]"_SBJL'P'D,G*1&N\C:R=I\>/F664$)^LA;2G$ M'#:LND+>J(=A'*G*?C$I,]A=L)T#G\K/)@1.K8%I+,UF+M7]N_:/FFT\2F^D M=!Y/JI(O%=)%0/ ;FLK.K$;SGW\?RM+!D0WP=&)Q^K>W#,%!V$ @@\4@B#D+ M6=.6RL\M,*Z]7)VJU 8$2./%>&Q9S+08Y5F%8HZ10G1SA*A7J3\UV1 =IB]0 MC^I68R*9#5W>P04S7UB?(AOC9[DW$4'^$JYKF&GPK9"5%3[[!>-8I/9V>OJQ:' M]Q<4T]0)-L21MK!7BB7#F[G#HT3'%-D_=;1%L0>;<8H0O&_Q4797,SZO M[U_S^]/-KQAO?DW;=@E[T0BE4:-O$V+3^OZFC7"!HG^R*>9)NK"CKF:*?M]? M8(KO!QB*G;W,DC"B1>01/0TG_).?;H(@_LG9Y1(GXY574M%-N[G3]\I\^4(< MY$MS9@B_7C5B.+2I%XR2N!$L6,5//9K1Y7<=O5-VZ@"I.K;M5Y]:2+)KZ4,J MFF>^0GXO"@%(9YA+,]B"[$R&BJGOV F[K+\#X;)'>'"42HB<^)XF8,,TN.Y MP\Q"1>D[1(_O;8+M^#DO&[N=O(*2;?@X1+ )Z?N@B20K0O?B5[KOM^/;Z^]/ MW5SN=5E=*'>;PY.J\.4-I-MQ3/5I#VR1H6>LNP3]3RZ3X[?AD,6OS0U>6MDQ=!DJKP&\Y_YP0\ MWH D;=<$ZAX$+LG'5\_;UB>ME3?O:OU4Y357;>0*Z+%BP&SZP!Y MM,,['AR)!-U#4F:-+^HK^!QEHMG=]^V]X:@$T2'=(C ML$G#%,F2:Q/1#=@0VWQ(O-*%B@T\[VHZGQ&!3)]P[",*N+DZ&4 ]M##R3&T8 M!Y:.#957:+$JWGW"._/WZ6B8:;:WOZ>%,C6QGSAW<6D'[WH_^N8<-N',V_0W M%]7?<7?*GG>5)5YY?QS<]-OULV_ZB;SV(D42):L6)S:5OKX?X*8NC(N[,+XNL8;0<41',.J[R\LZ -S#*N*T10$D7HH/'Z&0Y)@S%/LBU%H\ MHVI%G%/PBH %](S@I[1"0)>!1DO0'$:Y'X.1D_%:E.%YV.P4S HSX4+,?*'F M?869U1"BT0-$5$W'3)$$%\DXYVM[K(X7YWQ9TQY*VBYZ[AQZ?YG$=8!E5AZ;"F1U^B:" "[;G,H/: G[3! M_*+L@"K40:521N+KM A2:RYCO!CLWR[E)_/] SN9MP38GI/$'LR389L]S'@+#)\@C=JJ;G(1&M,7T?&@!Z(. M/FD<16BNQ3DR-K,+,VH7L^E5 [N(G^#MK<49WN-GT)!".-KI9'IS%TEU.*)I M9#.[9;&^S"/YM1?1*D$TH/C_X"5+F9PT[R5GOE VRJ@EKI,EUO[B M=CJ6O4H@PB?,)8?Y,25'.KP6>L+TK5(B#C4BDM M90;.<)TRY:O]5(KX5]?%?RKK*[NQ2.@T5R98%<;R2&$/\=>":+&1-IHO3.!_ MGKZO;4ZE7.'WV.%9)U,U$S"*J@;D5R!KK(K;2W7L8._*\ X9*D3C^1 /*:@A M(N&F>'TTXN^/1IK_6AE>=E^Z6[*1UV\LJ\W(?VLSFZC-),9N/^D%7P)7IWEV M5>W>MI>_D?%/X(T:_"8[?[50IBB.C86.07G%_^\N97Y.L^(>V=[\/A_?-=!< M?8)4[/)*ORA%>&^PXG@4@FS@&!H@6>8U$H4,L-[CNQ$WC+M7\M4O+X1+!Z\UGEWR'J=5HMM83EY\N'QMCUW=_'DH MYM8:T/.7FY71PLO-7K%^AXE;[WFWDTEY*24OK5#+*"WP],V'^'Y+S-I9=$G! MP1 =?1*'<&V>'5FKA(FKF\=:!ZQOFF(87S4E_.-YKPTHZ2U<9V>;/A!SA*(O MH%Q[V6GN_98K[/#EC]"U* K89?09@S/Y;8+*#49X2V([W;TSE\?ER,'C,WW4O M[K6;0O7VVX_VL-249*>1K>5'%Z[\:-V-\SV[?IMM7I+A?:?-KKNG/QB[D6R[ M4:QWS?:H51A_:EZ?ZY?WBMH>W6FMR=TX1]5OUMU]8W).)O=GCF*>?M9*(WV_ M-#FM:YI^^^G;Q?/Y^4GMU+9ZO<:E;0YHKB2=MPK?Z*?6[;AQZ?;UQMAH/S\_ MWN7W]^E9^_Z+='#0+/VOD^U7)S7B+Y/U!+ P04 " !K/!Q7ATFE MB PA !?_ %@ '1M,C,R-#0P,F0Q7V5X.3DM,2YH=&WM/6M7XDJVWUW+ M_U#7Z>FE:P4:$!^HQS4H=.LY/CA*S[GG?KFK2 K(&!(ZE4A[?_W=>U=5$EZV MV*!H,VMF6C&IVK5KOU\(>OQL./Z!PP?+1RR2'R/U2N5PH.<7_ M%=\KE5S1[74*A6+^/_W.!JM>-'_;V'C3)S:;P$56^T%'"'8&./ 0#Y*=!F$_ M"'DD6",,.J&0DG'?83<"/HWD^MJML /X_<^8A[ (*Q5*V^RSZW/?=KD'C\G8 MB^1<:>*EL'%^_&&[O,-ZKN>Y@<]RD+M2./B'N"_=_Q/. M^MIYX]K"!^Y=Q_4[C.//_Q%V!(\%?0%HQ$_#V!_P!W@O"ECY3T39[M&G\V5$ M4"X*^K1H\D$KB**@IS^;@K9&ETO!BLSV7-^U@0JB$&D!?HEWIX%F&['GO< 6([<'MX%;=+E7COGN6W! %+A._1QY.;.+W+%;?JQ%3@/ MM$'4%0"GX%%/("RP/X?#NS9S1-B#>XMOQWFV><6EP[\=("W7MY"4#>/D9,0[@K7<(!)VUP^\H// [* '[/+ MN'./\/D=8!RWW19PHYJ]X'EX$G8:)VPVB:[99K4&^]K=,(!M6="">P9*%XMZ%NT.Z QKKNWT!*!#X>Q_.C@=#YFX) M&>5 "-D>!SD,@ 6V!]!Y*2=O]JJMK?6UB-#M"H4!#8,Y NS/X;6.(OP[\4"O MHQ!"Y(&XAUT"7RBZ!AI'M+5B"? HX4]*,,_.?;@"Q\43@1A2UQR25H15)&G% M];5O6;783M1BJ-0B[9!@H1.#3/-M.+6OL#!5=>27F;<^>LZW.#C\2X#T!0KB M=M<5]P(Q"0_>\18(=-"C Y0YZO3:J+!)N<(],R[[<&XEAA1B/X82UY3I/8#2 M)9R"5%** !='VG\@@G=[>!%PK]G[A.4BX&E)=X;8A)=!/H)*ZZ+ 0FT=MSS7 M!DJ#YQRM0X:9<7U-\Y_U,:1S,LE=AUVZ=I<+CYVAD@DEDL1EOI8'R0&G;[-Z M(AVOVVW7!H)(CI9G&F% 3P@YD';$'@0/V4!CL >@,!_88 !'ZCXD*%M? R0$ M<0A'E!(M%,0%H-H+^BQ*Y0VI1. Z8@6@<1=%/.(I$2"P.+QEC;$:(EFQFN8O M9"@0@!&"U@(.%00=<+T$G>/"P> Y>!>0#S0MP"H"H !KOJ-5ALU#..\U@-P* M ]3GAL_!8*##)Q#@66")$) -* &-'BG1@:N([ZXD9ACF\FH-9#(@K]OC=&\H MI_*L"C\91-KP< 3Z$:T#W,U(4J4 $RN.@1$'?P,Z4=O EC[0OM)R9FO$L4O2 M[Q[)*]2(T'12 BQ*NQ'W'%;_%;DBRUNB5A#73<^5![X%Z<7'-]37QW785 M\D!\J"LC#K#H=;@DH [$>QL0Z!/QX;:\Y7IN]*"(VP,6"MD]]V)8( QZ],1T M#9'E@L1FA+N!M5I@^K3=*&4(6-HU.F%48>0UKR^SV 6CI6'8*>.^(6J_]H'2 M\7"7B2Q*B4:W5SJ^^_+91V*#?;QO54_/[7^>UYMEO&\5" MX9\;"W%0 "G-&[,R$$Y$8EP;R/ B!D6.FC7SQ,!UHBZ\F"_MN#YZ],W:\2-_ M'C,AVQQTS#$(/Q1D)FL1+U*I.QBU0R-P7 M02QG V7S]L^MU)M,'1 M_$9(-QC+F 6:$5_*GHZ33+"_9#<8L(QEQ[)N)E#=C!2"QE:H2 (MC2$#+L\: M^F;Z 9KG8,\ "A$R?0.(36O(: .*1<,I>(YT$RKV!FXG;!%0N&@2"UBLN)L; M"'&GKZ^$9E?0SL%_X2%;@)(R]SD;%+W 01-)@/;*2;ABL'L2.X2D:K6F'9QR M?D@M?&K>X/^A>EVI[J55W6;I;#S.$^WHV3NKT'SCRWYAWWAX%,Q);%HFA0>" M"U5!HH.!@%1P>1M\W .F0G)F&? =T39DMW].U&75EO$PAG58&0Q^#T3UX>3( MDG*Y0-UC"!>)NZM\%9&H![#*^8.T1MSZ]35R:E(37;DTC@"E"JX)"2SQ+7;O MR95AL'5+1!A6(7EE8RA=>?T^I:&T53 $+\HQN KEA9$372%%"892L/!U>O_+A>JX(=2#WQ]R6-9S4'FI#BPVZKMUE@0UT*Y,X?MS'2#Z\ES! -A8+.J6+ MB:8(-+VV0#$:FF$+LVR/*_#H=H0!R='5@5FES1T!]F4B( A2 MC($"_DB7<9]"Q !):E#$9 4.1JD$7//\ V")TTYF ME69@L)GX/7<]"BQF#(H1BP[M&9*1ZVM\B@S%73'N.D(0KZ2(YQ 1,$O]5R[' M/KO"?8(])VS? B*YR[4$W C V">8LR#M3H ( MP9QURPQB/B%F%#(6>IMCE09*R#WO@E^I1&&EPY90AY5*I41DI3$<%=IF3@RB M-W7Y4IL.M1U2 M]E*]E1B#%EBJ7E];A:%H<8^\0Y5!ZL6^6%^3#S(2RDM.5E%_8[;PO%&G6*6, M3% G!)4#+Z@(MU':X 3'L(D&6Z4"=;P-W7U0Q)C?4ELDD.;7URB6GFC-B2X[ M:%X*&-A _!S6TP'L',!!Q@LNIV+"\J'7![[1:0N,O%/4R,?$D+JYU&+&YW$K M)QCXRM[ U-,$6V!E.O]:8N?2I*N21!Y9CI2,3 UC%U]*C3N3ZVKPD'?@03OP MP'@+5,J( L: KBQ0+3 K.O".[^3@V2 \0*,U$AO'F0P\!1J1+;0(3!+&)I*7 MRI%1YS/)I2FGHA$Z[683\ :"C!2GE1C_>32)%AS]CO@;O@"^&,%"?$F).&C94KW<%D M6!;GC(/#(T@,TY+F8B;7K.2Q\D79UB8$IRUKE3@TT5ZS/0HF4@Q:U(PC>2C7 M2RGP'^9[04@)']A0 "EB 7C'3O/LTOY#^#[)F],N=T/8AZI?@+E.,(V/^;N1W)R5\9B5 M\Y]6^Z%8F T0W"E34HB;C\!&]F /Y)(!T&(-L(54[I_J-^K7^%H#?'T!R\62 MG;B!Q(H*6V3ET6R J7C' 6Q_2UV0U4R= G2YTXM25(=N"Z?V0)-L]_!'$OS MER2FR1;[[H(1)+#08A8P/A0+^7W64J7%5AHST6*.>2@RL3XV%#F5?-C&LCZ5 M)5.@RT3Q8?0"\!KF%7P:P6EP=1; [OQ@X FG(Y25&-N ;-F.T59'[SX4-CC] M)MQD5*#L5;#"W5H+U_1")HQPY@$VL$;<%%[KZS>7TP\URA&2_[4)8\B M=L(Q%R&1[K\('TP4#\1'[ .EH(0]8%5/!L@Q1LYF7UI?(U%DI/V$-?+L3)"\ M0M_.5>[LR",,S*IJ>._Z?,A. XM/5PX#6NP8:^O1UO1M59J+[.2+.%2UPFCK M&DL6A"2F)(%W6K'K1:0(/-%!2PUCS6C91JP78%$G16*I\N">JC"SN1YC"I/9 MK"HKS6<6K*>,5@X2D'SNE)_!Z-8A;5TMAT)1GR\QVJ?8LI)<;8NIV"'\HRN? M\ @C6,,J8!D0(*3I3/E:1E:MKW$L@R87)H_J25^ E0I;<_ETC4 DO@N*H:9% MC F<9Y$'5^6!11M0<0V6/)"!#:"P31"]U!!!T1 \X/\ Q#;? B(Q%Z(QHI$W M"6:L-K25W4]E=0 7J)8^EC.V="^%*N^.0^/;^Z(34/@"\:R 2_ ,ER9\2:&2 M842K4N]+T@!5-HPGQ 'TY_",VJ5'&XH-Y3B0:XDHX7 MM(AR#6 ==$RP:AOVU.6CU/9C4"=!'85T;B!@.AL5H2:*$.D=L*#1B')D KDF M6*3J9&ZK:-=*K?Q::@6L_E.BEIFM_J$VM:2(60<^&DKP7F.4$JEV\[QQC>;_ MEHKRGJ-EBQ(M6UMC/P\.%*/9&FIBD,!S6*E@E2I[UDZAP"1PHRJ]0LN.ZL,# M^\[D(5642$LW;.A"@P^L/REF@T3[.A3X& !_BL3:T]7P%"R-0YM,ZTRH0H.' M(5'6ATL)7402AH0#%8B9!0JM\P"8#\6]/!P>91KMH&)%O-,)03-$8K2Q$&6G MLEJ3 K+ W)_2;+,!XF#$F<1[@A&J@L/FIMC75<)X'ZJ10&:Z>Y)]TL9OH9AZ(=Z,LZ+<8&N\!PI3VF1F^UAYTXCU+RCMA903\0M(_T]PY'#V>#90; 2:W MS5F-3!P+;%SJ@E(U)4#HU%+4%2!HHO !F[;\N,VSMJBNO@1K^/3R=,MB0^[1 M;+"HUJLF&GID^>G6J_=9R%%:%7*L"CF6@59/CDC38/3]L^0[Y7@,7/1:?2A'= M")4JMGZ29C7EQFDK=V)0D]K3L07Z$#1O'&+Q""4HE/5 V6?RB@*T69AI+ >( M<'[(RI!><5E;IXW!#@3'-IO-JF7"@YNZ9W>+U34!*M/8M/(:LEQ?,_5::I;! M",5M*S_P0W$[7S'T;PTU^7PHYLL)9SRZ5BD_MKOJ8 ;G'&P^U=;F8AE73(ZX M+H] OM%-$<.%;YIE5-&&6H8&!O2I,]\7&."3T5!1"GGEN19N2(< ('C23N'+ M3(02 ,J*#)QC *9P-RU.YL# #%S:IR%\7.:*:+>3/\5Z5R)B%V#0*:["WSPT[WZDT[@$O;6?828][R5,ZPG\ M)ZU5RE2:@";?TNLIY&HM-9U\I)*@,.B>!;7TM4_B)@&)4 M<:3">&3J'Q7I9(MSDP-'@X#U0#NEVPR=?,S.-&DJC@F8EE!%^Z[NW-<$@?'7 M23>O"W7Q H>#KWEVPG5M!A^=BZ2Z#OI*GZD(JHOM!)ED'0)"DYBH*L/F_LB8 M')J (#C.N\(R+M-"A_DOKCOL*"F$JE7/S\+A;)E"B]'Y39]-+P@07Q"J"10@ M)_O4ZL#NL3"-&2GW]7@P&.0YT5EF&H_, _0T_6ZI1_" )B_%N@ M>:&3"F]9#I[J!A&9G$?5]+E49R2EZ5Q97\/64!R&!=(JCH3)5+057G*>QDNZ MCAF+AA)'EPEJ\C,V65LX9!5G:B<\/LARL 5V6T0=GR1FE.RQ:-B3"O-HP8/9 MTU"-C:!2=#,BRP1;5-<-!5/&1H(WZT?KV T!,""0Q^&7IDX_D2Q:7:V M8.3V,G@8GF&CA@VJL8#):*OA=65F1%L&',/2PP-/TV$]B?!2C:VF4TJ5GJ!6 MTX9VLG0&*0)_##8!84$N9AFG$HBG<$1)^M3&'C8&Z%I93)4/:3+".9HYE MH,].,_LK"!V)1;%=K.W1K ,DLP"-!]A/L!*A,I]A#]0 M[5LB\%("(EQ'EIIIV 9*#E()D*4YB\R"Z;(/**3K>FG)L5',"KKI[]&R(:5O MT9VFCIT89"\(854('OJQV=2&](3TF_A\B4Q!,(SCT/ ML>*2X3@DJ3I49 MY@&^YF_SH%,3W81@U;^CM=JAK((NDEE?V\2G;^NG6UN4R'Y .LS@6CP$_M"< MR61+G>/6%?;)8=468)7;49R9$:L:6EM8(0OTK6U-XW3DU]=N#&[8,&IT+=6! M*6KLX2Q'=%6#'E7-^DJ@FS&WJD'T/H!_:2J7]9BT3567E0S,L%1%:#)_QL / M6*$IC9G*8!G%#MGL(_K-*$$*8&OC-]411A4<_D /(#$HM]T3B5L!A$%^BX9F M9.-#72ZFQ15Q Z$$=\"ZCI:(!D+X8Z=X&!KE._E/ARI^9Y1_" 1Z!XS=#0(R MJ@'^V%,.G*%%X@3,,]T3;)[[+78=,REM3)L=9OS!#T=M3]NAMKFA1TV*/.KXM;'KP*!BB)H.@]-43=X$1\%TL)E3O8G.S MRN5I.I=4K!!1V9D7R!B=*">P8R4N!C1*%E$@4EZ$19-)'K"QV],]SR$ZY\:. MH '?@Z[M-X$6P8\B*J:G[(RLE!5R4BJ21:D0R) M6YPYF_6PC!U*'=X2EZ,K'Y!#*+[3.#(J]D[;FL"L7FX'ZPF%+=NKPI958LO]3IKGM5OJHWZU^;YZ:W%+BY.ESM<\.3C MG5Y?U>I7M_4:@Y]NKR_.:]4F_')2O:A>G=;7UV[/ZO7F[<*_ F@B;)M?KZI? M:^< S]8K +!)\]O!6 5M)[=>N[[)B"DE_ZCGI"]!4IF?,#Y#R1S,/3V=P3=( M+CV24U*R;L.(KTSN"$_B?F ;/P6IP]=U M""+;09LQ%G M8&["T7\2^K>'N5K]M'YY4K]AV\4$>Z5EP!ZE!)_$9'#(L<$H8:>U62J4K=+V MOE7:V=F:P(CS0+;KHSMQP'*%?!%SP2E6L&8",\1%E2*N2G"]Y2A>'V/[B?!F M'AZ^;E6B,5EJ//JB_I*W9[PYMN7;@_CG:.PO-7QG"F']+ ,CL+-2V:D)UA.U M':S(;;D@7KA(TZ;,WO8,ELRS)9LF.2Z[4\IC2C\!Q>,W;4RVGS_FT%5]F'*0 MXBR6X>,;:6H"E%J%W25BWRY8N[M[*WGSBE>P4[(* M.V]8YKR&J5/*[\P@:K3[K$3-HD4,@?8,"J?W]+>5+=A8?[']9Y,R^E)?5IWA[$BU10:>^&J[X6D K%^ M*-HBQ'(6G(XN=3=#KY49Z.4(+.&-5K2Y7!"_*8?M>?D&+Z74@X__J*S$XY)! MO/SV^TQ1R:JMI_7U^0-6J$XCN?DG'A9J[\W7F"M:Q?)8G/"E3.>W@Z=R\:60 M]*;TP,^G#H!)PUBDJ8-5S.ZE D:[5GD5L7O-"ZA8.[MC-52K>-U"$P,9$W0E M:5XL-+UG[19?-3+]J]] Q:KLC]4^O!U1\X:LFJ$XID6471WFH4;?&J[LE4AXL(J4Y6Q6]STIF%KYA9 M.,0O*2D4Z'\FUQ!'W2#$V;\6&K*549L\2(B?C M0J2\8Q7V*U:I6'IA(5(L5U929/[IA/*^5:[LKL3($F)KV>V2G["/+R=6.*P: MVY8,XJ749,_/+Y^J+^33FFSG6=;P2N7\M"T&XFAEMRX?KMZCNE%\?^[CU 0< MY:59O[AK[6SO63L[>Q-XOPB'V"O _W:R8J!DE?>+UDYY^TF6+6P!+^#_]K8G M;%&Q=L&2V-XK9WN&'M5,::\!=B91ME;81^QO5ZR]_=?"_INR7>96 M(_/T/H&5Q%D(S>^6POQYB%QWECKK#>_CJ7Y2*)5K^VJ MUW8Y;V&Y>FTSW[PVAU&MZO_S)"]&Q,.G#-@NKP9L+V+ ]O.I M88QOGCV ^PD$\DH#NE^<5X9EPFJ ]\@ []LF_'-9OVJNKUU_9M<-.'SS'!Y@ MU2M\\K)Q4S^#U\[_76<7U[>K =_S'_ ]0A SC?E^^M9/&PC^_#'?CZ6D'\NS M9I#]&14X/3 0*/W4*((?C9C>&9UY_JB7-=O>D^@#;/^S&Y 3E]=7S;-;5@>N MJN$@:0 MF\KE H)U?ZW-\OKF^U(?\7#^Y M^5J]^9N5+?T))8[4CYOG5Z?U!HK!+?5)\WI1=_MT=WD"STUUZ9_ B$]Y=ZX7 M^E+<.6D:_GL^[-,#/:]UV$DZ=HQ*0/Y\@E\?ANYGR-8FC1QT9KO[( M+H_?TLAD\1FA_>%@]">OE\1SK4IYK-3XZ8>=E4B7[?A6>7S,S2]S^E+)*A?& M"O]^F>/O6+N5\:]Z^BD8E]P0^2)\^LIX^F)4I^?Z^IM+[\6,CMB,FF@VQ#US MH:0RK[(]L3)OCH3\J@?SG@-M77O^<3[EK%TL1VCO=ES%P$4K)V M&/2,Q G\=R1I-N8D9I;R<',3,4MYNGF)ET57.,X:I*7O)7-] M.^@)MJE-ERV+^6+5,;R"^->#>!E5_CDFD(2,-)N^'VW_L>=PV?VYI9;<*OT% MCEC3+<"5M+F5Z?5Y3KB2MJ\CSC&E8B8A[$,-<*SUP]% M%Z0.#I+ CU];[$S\ HWW$,V8T\&6+I QGW-M%ZUR<6Q:[SLXV*+"%YDFJ+GW M-..\=%_]VP%* )/FZ$ M9T+(<]NEV@\Z0K FF)2\+V+0,O-<'1&3OT/$_(O31E%FGSPHDF6^U:HGOK/; M*.3Q/%'2/+OY>MND=2/1<6V&L]AB'[3[O*^6 _S_BKIA+"-I+SNR@>\OA>-R MP_3SYGE8W\ \UW5KW&&)S2S M[ARRZS[QS &[X#):GM[6A36:CF'ZT\EU[>]C_.&L>7EQ_/]02P$"% ,4 M" !K/!Q73T+ZC30# !# $0 @ $ 87!G92TR,#(S M,#@R."YX&UL4$L! A0#% @ :SP< M5[K!4=)=!P Z5< !4 ( !E X &%P9V4M,C R,S X,CA? M<')E+GAM;%!+ 0(4 Q0 ( &L\'%>EW_JFO1( )EI 2 M " 206 !T;3(S,C0T,#)D,5\X:RYH=&U02P$"% ,4 " !K/!Q7ATFE MB PA !?_ %@ @ $1*0 =&TR,S(T-# R9#%?97@Y.2TQ :+FAT;5!+!08 !0 % $D! !12@ ! end